Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710619 · ClinicalTrials.gov registry record
Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 52
- Enrollment target
NCT00710619 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 52 participants.
The verdict
NCT00710619 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
This study is conducted in the United States of America (USA). The aim of this study is to investigate the at-home-administration of bypassing agents for treatment of bleeding episodes in patients with congenital haemophilia with inhibitors to factors VIII and IX. We are further investigating how bleeding episodes affect the quality of life of the patient and their family or caregivers.
Interventions
- DRUG activated recombinant human factor VII
- DRUG Feiba VH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00710619
The ClinicalTrials.gov registry entry for NCT00710619 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which activated recombinant human factor VII is the first listed.
NCT00710619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00710619 about?
NCT00710619 is a clinical study titled "Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX". This study is conducted in the United States of America (USA). The aim of this study is to investigate the at-home-administration of bypassing agents for treatment of bleeding episodes in patients with congenital haemophilia with inhibitors to factors VIII and IX. We are further investigating how bl...
What is the current status of trial NCT00710619?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2008-06. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00710619?
The interventions under investigation include: activated recombinant human factor VII (DRUG), Feiba VH (DRUG).
Who is sponsoring clinical trial NCT00710619?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.